Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021） 2023-01-30 11:00
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD 2023-01-18 07:00
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 2022-07-04 13:34
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules 2022-01-18 10:41
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx 2021-10-15 12:00
1 2